本帖最后由 老马 于 2012-1-13 21:20 编辑 , J( b* n- e# S8 g
$ }2 o; H; w! A7 F8 o
爱必妥和阿瓦斯丁的比较) R9 b$ H# |. \* g# U% k6 Q* [* x5 k
2 N9 V! w- H6 t7 x/ T1 B4 N' b: z# L
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
! H9 r9 L$ `; E$ G0 G) M
' B* c L. b* G* n
! X: u6 P2 G$ j4 z; O# M, u+ s8 K6 Uhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
* p# W# l7 K5 L( f==================================================- d d* C9 p4 m4 f& z
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)2 ^" S, u% E+ e$ K2 ]* z
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
6 K1 F) d0 N; vResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
0 `! q; P9 m" @, V
|